If you have facial acne, you’re not alone. Many teens struggle with acne at some point and it’s not uncommon for people to continue to fight acne outbreaks well into their 30’s, and even 40’s (click this link to visit our acne page and watch our acne video). Whilst there are many topical products on the market to help fight acne, they do not work for everyone. Medications can also help but these can sometimes cause uncomfortable side effects. If these treatment methods have not worked for you, or are options you have decided not to pursue, Sebacia might be right for you.
This pioneering non-invasive treatment has been trialed in the US and is FDA approved. Sebacia has recently arrived in the UK after obtaining CE approval. This means Sebacia treatment meets European health and safety legislation. The LDC is taking part in the UK trials.
HOW DOES THE SEBACIA TREATMENT WORK?
The Sebacia Acne Treatment uses a specialized formulation containing gold microparticles (SEB-250).
SEB-250 is a topical liquid that is applied and massaged into the skin by your clinician. The procedure delivers SEB-250 into the sebaceous glands.
A hand-held laser is then applied to the skin, heating the Sebacia Microparticles in the sebaceous glands.
This targeted heating is designed to affect the sebaceous glands to address the three factors causing acne and improve the appearance of your skin over time.
The procedure takes about 30-45 minutes.
Anesthesia is not needed and you return to normal activities immediately after the procedure.
After the procedure, you will have some redness in your skin, but this typically returns to normal within a few hours.
ADVANTAGES OF THE SEBACIA ACNE TREATMENT
Localized treatment that targets 3 of the underlying causes of acne:
P. acnes bacteria (the bacteria responsible for acne)
If you are approved for the trial you will need 3 procedures each lasting 30-45 minutes with no downtime from school or work.
May eliminate the need for antibiotics or systemic prescription drugs.
EFFECTS OF SEBACIA ACNE TREATMENT IN SEB-03 EUROPEAN STUDY
Mean inflammatory lesion reduction at 12 weeks 49%.
Mean inflammatory lesion reduction at 7 months 69%.
Known allergy to gold, ethanol, diisopropyl adipate, Polysorbate 80, or polyethylene glycol.
If you are interested in taking part in the trial and would like to find out more please contact us here at LDC. Each patient will be assessed for suitability by a clinician.
Connect with us on
Fill out the form below and we will get back to you as soon as possible.